# STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia

> **NCT00015834** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 46 (actual)

## Conditions studied

- Blastic Phase Chronic Myelogenous Leukemia
- Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Relapsing Chronic Myelogenous Leukemia

## Interventions

- **DRUG:** imatinib mesylate
- **DRUG:** cytarabine

## Key facts

- **NCT ID:** NCT00015834
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-05
- **Primary completion:** 2003-04
- **Final completion:** —
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2013-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00015834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00015834, "STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00015834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*